264
Participants
Start Date
September 1, 2021
Primary Completion Date
November 30, 2024
Study Completion Date
October 31, 2025
STMC-103H
STMC-103H is a live biotherapeutic product (LBP) containing a consortium of intestinal bacteria
Placebo
Powder containing excipients found in STMC-103H: magnesium stearate, mannitol and silicon dioxide.
The Children's Hospital at Westmead, Westmead
Murdoch Children's Research Institute, Parkville
Monash Children's Hospital, Clayton
Queensland Children's Hospital, South Brisbane
The Women's and Children's Hospital, Adelaide
Fiona Stanley Hospital, Murdoch
NYU Langone Fink Children's, New York
Mt. Sinai Jaffe Allergy Institute, New York
Northwell Healthcare, Great Neck
University of Rochester Medical Center, Rochester
Johns Hopkins University School of Medicine, Baltimore
Coastal Pediatrics Research, Summerville
Tribe Clinical Research, Greenville
Children's Healthcare of Atlanta, Atlanta
Cincinnati Children's Hospital, Cincinnati
Riley Children's Health at University of Indiana, Indianapolis
University of Michigan Health, Ann Arbor
Univ. of Wisconsin-Madison/Jackson Research Group, Madison
Lurie Children's Hospital, Chicago
University of Chicago Medicine, Chicago
Arkansas Children's Research Institute, Little Rock
UT Southwestern/Children's Health, Dallas
Dell Medical School at UT Austin, Austin
Children's Hospital Colorado, Aurora
University of Arizona Health Sciences, Tucson
UCLA Health, Los Angeles
Rady Children's Hospital - San Diego, San Diego
UCSF Benioff Children's Hospital, San Francisco
Seattle Allergy and Asthma Research Institute, Seattle
Boston Children's Hospital, Boston
Centro de Neumologia Pediatrica, Caguas
Siolta Therapeutics, Inc.
INDUSTRY